RECURRENT GENE FUSIONS IN PROSTATE CANCER
First Claim
Patent Images
1. A method for identifying prostate cancer in a patient comprising:
- (a) providing a sample from the patient; and
(b) detecting the presence or absence in the sample of a gene fusion having a 5′
portion from a transcriptional regulatory region of an SLC45A3 gene and a 3′
portion from an ERG gene,wherein detecting the presence in the sample of the gene fusion identifies prostate cancer in the patient.
2 Assignments
0 Petitions
Accused Products
Abstract
Recurrent gene fusions in prostate cancer of androgen regulated genes or housekeeping genes and ETS family member genes are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.
-
Citations
18 Claims
-
1. A method for identifying prostate cancer in a patient comprising:
-
(a) providing a sample from the patient; and (b) detecting the presence or absence in the sample of a gene fusion having a 5′
portion from a transcriptional regulatory region of an SLC45A3 gene and a 3′
portion from an ERG gene,wherein detecting the presence in the sample of the gene fusion identifies prostate cancer in the patient. - View Dependent Claims (2, 3, 4, 5)
-
-
6. A method for identifying prostate cancer in a patient comprising:
-
(a) providing a sample from the patient; and (b) detecting the presence or absence in the sample of a gene fusion having a 5′
portion from a transcriptional regulatory region of an FLJ35294 gene and a 3′
portion from an ETS family member gene,wherein detecting the presence in the sample of the gene fusion is identifies prostate cancer in the patient. - View Dependent Claims (7, 8, 9, 10, 11)
-
-
12. A method for identifying prostate cancer in a patient comprising:
-
(a) providing a sample from the patient; and (b) detecting the presence or absence in the sample of a gene fusion having a 5′
portion from a DDX5 gene and a 3′
portion from an ETS family member gene,wherein detecting the presence in the sample of the gene fusion identifies prostate cancer in the patient. - View Dependent Claims (13, 14, 15, 16, 17)
-
-
18. A composition comprising at least one of the following:
-
(a) an oligonucleotide probe comprising a sequence that hybridizes to a junction of a chimeric genomic DNA or chimeric mRNA in which a 5′
portion of the chimeric genomic DNA or chimeric mRNA is from a transcriptional regulatory region of an SLC45A3 gene and a 3′
portion of the chimeric genomic DNA or chimeric mRNA is from an ERG gene;(b) a first oligonucleotide probe comprising a sequence that hybridizes to a 5′
portion of a chimeric genomic DNA or chimeric mRNA from a transcriptional regulatory region of an SLC45A3 gene and a second oligonucleotide probe comprising a sequence that hybridizes to a 3′
portion of the chimeric genomic DNA or chimeric mRNA from an ERG gene;(c) a first amplification oligonucleotide comprising a sequence that hybridizes to a 5′
portion of a chimeric genomic DNA or chimeric mRNA from a transcriptional regulatory region of an SLC45A3 gene and a second amplification oligonucleotide comprising a sequence that hybridizes to a 3′
portion of the chimeric genomic DNA or chimeric mRNA from an ERG gene;(d) an oligonucleotide probe comprising a sequence that hybridizes to a junction of a chimeric genomic DNA or chimeric mRNA in which a 5′
portion of the chimeric genomic DNA or chimeric mRNA is from a transcriptional regulatory region of an FLJ35294 gene and a 3′
portion of the chimeric genomic DNA or chimeric mRNA is from an ETV1 gene;(e) a first oligonucleotide probe comprising a sequence that hybridizes to a 5′
portion of a chimeric genomic DNA or chimeric mRNA from a transcriptional regulatory region of an FLJ35294 gene and a second oligonucleotide probe comprising a sequence that hybridizes to a 3′
portion of the chimeric genomic DNA or chimeric mRNA from an ETV1 gene;(f) a first amplification oligonucleotide comprising a sequence that hybridizes to a 5′
portion of a chimeric genomic DNA or chimeric mRNA from a transcriptional regulatory region of an FLJ35294 gene and a second amplification oligonucleotide comprising a sequence that hybridizes to a 3′
portion of the chimeric genomic DNA or chimeric mRNA from an ETV1 gene;(g) an oligonucleotide probe comprising a sequence that hybridizes to a junction of a chimeric genomic DNA or chimeric mRNA in which a 5′
portion of the chimeric genomic DNA or chimeric mRNA is from a DDX5 gene and a 3′
portion of the chimeric genomic DNA or chimeric mRNA is from an ETV4 gene;(h) a first oligonucleotide probe comprising a sequence that hybridizes to a 5′
portion of a chimeric genomic DNA or chimeric mRNA from a DDX5 gene and a second oligonucleotide probe comprising a sequence that hybridizes to a 3′
portion of the chimeric genomic DNA or chimeric mRNA from an ETV4 gene;(i) a first amplification oligonucleotide comprising a sequence that hybridizes to a 5′
portion of a chimeric genomic DNA or chimeric mRNA from a DDX5 gene and a second amplification oligonucleotide comprising a sequence that hybridizes to a 3′
portion of the chimeric genomic DNA or chimeric mRNA from an ETV4 gene;(j) an antibody to a chimeric protein having an amino-terminal portion encoded by the DDX5 gene and a carboxy-terminal portion encoded by the ETV4 gene.
-
Specification